Sonoma Pharmaceuticals (SNOA) Competitors $3.83 -0.25 (-6.13%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$3.94 +0.11 (+2.87%) As of 10/17/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNOA vs. CVKD, ENLV, XCUR, LPTX, MTVA, PASG, PRPH, ALLR, MIRA, and TAOXShould you be buying Sonoma Pharmaceuticals stock or one of its competitors? The main competitors of Sonoma Pharmaceuticals include Cadrenal Therapeutics (CVKD), Enlivex Therapeutics (ENLV), Exicure (XCUR), Leap Therapeutics (LPTX), MetaVia (MTVA), Passage Bio (PASG), ProPhase Labs (PRPH), Allarity Therapeutics (ALLR), MIRA Pharmaceuticals (MIRA), and Synaptogenix (TAOX). These companies are all part of the "pharmaceutical products" industry. Sonoma Pharmaceuticals vs. Its Competitors Cadrenal Therapeutics Enlivex Therapeutics Exicure Leap Therapeutics MetaVia Passage Bio ProPhase Labs Allarity Therapeutics MIRA Pharmaceuticals Synaptogenix Sonoma Pharmaceuticals (NASDAQ:SNOA) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment. Do institutionals & insiders believe in SNOA or CVKD? 2.0% of Sonoma Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 24.6% of Sonoma Pharmaceuticals shares are owned by insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, SNOA or CVKD? Sonoma Pharmaceuticals has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Does the media refer more to SNOA or CVKD? In the previous week, Cadrenal Therapeutics had 4 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 5 mentions for Cadrenal Therapeutics and 1 mentions for Sonoma Pharmaceuticals. Sonoma Pharmaceuticals' average media sentiment score of 0.34 beat Cadrenal Therapeutics' score of -0.43 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sonoma Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cadrenal Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is SNOA or CVKD more profitable? Cadrenal Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -23.87%. Sonoma Pharmaceuticals' return on equity of -50.00% beat Cadrenal Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sonoma Pharmaceuticals-23.87% -50.00% -16.79% Cadrenal Therapeutics N/A -265.37%-196.38% Which has higher valuation and earnings, SNOA or CVKD? Sonoma Pharmaceuticals has higher revenue and earnings than Cadrenal Therapeutics. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSonoma Pharmaceuticals$14.29M0.44-$3.46M-$2.46-1.56Cadrenal TherapeuticsN/AN/A-$10.65M-$8.88-1.53 Do analysts recommend SNOA or CVKD? Cadrenal Therapeutics has a consensus price target of $32.00, indicating a potential upside of 134.78%. Given Cadrenal Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cadrenal Therapeutics is more favorable than Sonoma Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryCadrenal Therapeutics beats Sonoma Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Sonoma Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNOA vs. The Competition Export to ExcelMetricSonoma PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.71M$2.62B$6.09B$10.48BDividend YieldN/A57.79%5.73%4.80%P/E Ratio-1.5622.9984.5227.09Price / Sales0.44565.31519.33179.64Price / CashN/A168.7137.1661.22Price / Book1.405.3212.246.52Net Income-$3.46M$33.06M$3.32B$276.75M7 Day Performance-5.20%2.44%1.26%1.97%1 Month Performance-10.09%6.46%6.29%2.23%1 Year Performance21.20%-5.42%59.93%35.58% Sonoma Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNOASonoma Pharmaceuticals1.0902 of 5 stars$3.83-6.1%N/A+30.7%$6.71M$14.29M-1.56180News CoverageGap UpCVKDCadrenal Therapeutics2.9076 of 5 stars$13.58+0.4%$32.00+135.6%-16.4%$27.84MN/A-1.534ENLVEnlivex Therapeutics2.6921 of 5 stars$1.13-1.7%$10.00+788.9%-35.0%$27.33MN/A-1.9470News CoverageXCURExicure1.1733 of 5 stars$4.27-0.1%N/A+56.0%$26.92M$500K-1.1050LPTXLeap Therapeutics2.8345 of 5 stars$0.63-17.4%$3.38+434.9%-76.3%$26.19MN/A-0.4040News CoveragePositive NewsAnalyst DowngradeShort Interest ↓Gap UpHigh Trading VolumeMTVAMetaVia1.6265 of 5 stars$1.05-2.8%$7.50+614.3%N/A$25.41MN/A0.008PASGPassage Bio3.0958 of 5 stars$7.96+0.3%$75.67+851.2%-32.3%$25.29MN/A-0.44130PRPHProPhase Labs0.6692 of 5 stars$0.61+2.0%N/A-79.5%$25.26M$6.77M-0.48130Positive NewsGap UpALLRAllarity Therapeutics2.2175 of 5 stars$1.74+5.2%$9.25+433.1%-15.8%$25.18MN/A0.0010Gap DownMIRAMIRA Pharmaceuticals0.3656 of 5 stars$1.31-3.0%N/A+48.6%$24.98MN/A-2.672News CoverageGap DownTAOXSynaptogenix0.0603 of 5 stars$7.08-8.2%N/AN/A$24.71MN/A-0.354News CoverageGap Up Related Companies and Tools Related Companies Cadrenal Therapeutics Competitors Enlivex Therapeutics Competitors Exicure Competitors Leap Therapeutics Competitors MetaVia Competitors Passage Bio Competitors ProPhase Labs Competitors Allarity Therapeutics Competitors MIRA Pharmaceuticals Competitors Synaptogenix Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNOA) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersHoly ****... This could actually MAGAA new document circulating from Washington is stirring major controversy — one that some say could redefine Am...StocksToTrade | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA Worldwide Gold Lockdown Is Now UnderwayCentral banks around the world are hoarding gold at one of the fastest rates in history — and former Goldman S...Stansberry Research | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonoma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
